Previous close | 0.8074 |
Open | 0.7959 |
Bid | 0.8000 x 3000 |
Ask | 0.8045 x 800 |
Day's range | 0.7705 - 0.8198 |
52-week range | 0.6000 - 3.5600 |
Volume | |
Avg. volume | 936,501 |
Market cap | 92.684M |
Beta (5Y monthly) | 1.51 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.5300 |
Earnings date | 08 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.51 |
BAINBRIDGE, Ga., April 22, 2024--Danimer Scientific, Inc. (NYSE: DNMR) (the "Company" or "Danimer Scientific"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today, that on April 19, 2024, it entered into an asset-based revolving credit and security agreement with Mountain Ridge Capital secured primarily by the Company’s accounts receivable and inventory.
The heavy selling pressure might have exhausted for Danimer Scientific (DNMR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
BAINBRIDGE, Ga., March 28, 2024--Danimer Scientific, Inc. (NYSE: DNMR) ("Danimer" or the "Company"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today financial results for its fourth quarter and full year, ended December 31, 2023.